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Abstract
Background: Alpha B-crystallin (CRYAB) is a protein that functions as ‘‘molecular chaperone’’ in preserving intracellular
architecture and cell membrane. Also, CRYAB is highly antiapoptotic. Abnormal CRYAB expression is a prognostic biomarker
for oral cancer, while its genomic variations and the association with carcinogenesis have never been studied.
Methodology/Finding: Therefore, we hypothesized that CRYAB single nucleotide polymorphisms may be associated with
oral cancer risk. In this hospital-based study, the association of CRYAB A-1215G (rs2228387), C-802G (rs14133) and intron2
(rs2070894) polymorphisms with oral cancer in a Taiwan population was investigated. In total, 496 oral cancer patients and
992 age- and gender-matched healthy controls were genotyped and analyzed. A significantly different frequency
distribution was found in CRYAB C-802G genotypes, but not in A-1215G and intron2 genotypes, between the oral cancer
and control groups. The CRYAB C-802G G allele conferred an increased risk of oral cancer (P=1.49610
25). Patients carrying
CG/GG at CRYAB C-802G were of lower 5-year survival and higher recurrence rate than those of CC (P,0.05).
Conclusion/Significance: Our results provide the first evidence that the G allele of CRYAB C-802G is correlated with oral
cancer risk and this polymorphism may be a useful marker for oral cancer recurrence and survival prediction for clinical
reference.
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Introduction
Oral cancer, which is a leading cause of death and
disfigurement around the world [1–4], has ranked on the 4
th
cancer in Taiwanese male population [5]. There is an urgent need
to develop routine preoperative markers to spare patients with
poor prognosis after surgery or other treatment and on the other
hand, identify patients at risk of early recurrence and justify
prophylactic neck dissection and adjuvant concurrent chemor-
adiotherapy as well as those who could benefit from various
treatments regardless of their tumor size or staging. Those who are
identified at higher risk of oral cancer recurrence and/or
metastasis should be detected earlier and followed up more
frequently to enjoy longer life with the development of useful
markers for prognosis prediction.
Alpha B-crystallin (CRYAB) is a member of the small heat
shock protein (sHSP) family and a molecular chaperone expressed
in various tissues [6,7]. Recent evidence has established that
CRYAB presents not only in eye, but also in heart, skin, brain,
spinal cord, and lung tissues [6,8]. In mammals, there are three
classes of crystallins: alpha, beta, and gamma, each contributing
equally to the total mass of the lens. From the proteomics or
protein level studies, it has recently been recognized that CRYAB
may have a role in cancer development. In 2005, it is reported that
CRYAB was down-regulated at mRNA level from oral cancer
patients compared with normal oral mucosa [9]. However, in
contrast to the highly expression in normal oral mucosa, patients
with negatively or lower CRYAB detected in their tumor sites had
better disease-free survival rates than those patients whose tumors
stained strongly. On the contrary, it was reported that from a
proteomics screening in Taiwan, CRYAB was significantly up-
regulated in the primary tissue from oral cancer patients [10]. In
2010, similar results were reported in a mice oral cancer model via
concomitantly 8-week treatment with 4-NQO (200 mg/mL) and
arecoline (500 mg/mL) [11]. Despite of the disagreements raised
among different ethics and populations investigated, the genomic
status of CRYAB and the linkage between its genotype and clinical
outcome are largely unknown.
In order to understand the genomic role of CRYAB in oral
cancer, we have chosen three single nucleotide polymorphisms
(SNPs) of CRYAB, A-1215G (rs2228387), C-802G (rs14133), intron
2 (rs2070894), and investigated their genotypic distribution in a
large Taiwanese oral cancer population. In addition, the two
clinical outcomes contribute to the highest death rate of oral
cancer, metastasis and recurrence, were analyzed of their
associations with CRYAB genotypes.
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The clinical characteristics of the oral cancer patients and
controls are shown in Table 1. There were no significant
difference between both groups in their age and sex, while the
patients are much higher exposed to the environmental risky
factors for oral cancer in Taiwan, smoking, alcohol drinking and
betel quid chewing habits (Table 1). The frequencies of the
genotypes and alleles for the CRYAB A-1215G, C-802G, and
intron 2 for the participants are shown in Table 2. Genotype
distribution of various genetic polymorphisms of CRYAB C-802G
is significantly different between oral cancer and control groups
(P,0.05), while those for A-1215G or intron 2 were not significant
(P.0.05) (Table 2). Also, the allele distributions of the CRYAB C-
802G (P=1.49*10
25, OR=1.51, 95%CI=1.25–1.83), not those
of A-1215G (P=0.8593, OR=0.91, 95%CI=0.31–2.62) or
intron2 (P=0.1366, OR=1.16, 95%CI=0.95–1.41), is found to
be associated with the susceptibility for oral cancer (Table 2). To
sum up, the G allele and GG or CG genotype of CRYAB C-802G
are associated with oral cancer risk and may be biomarkers for oral
cancer detection. The representative PCR-based restriction
analyses for the CRYAB C-802G polymorphisms are shown in
Figure 1.
To evaluate the prognostic value of CRYAB genotypes, the
relationships among disease-free survival, recurrence, metastasis
and CRYAB C-802G genotypes were analyzed. First, the oral
cancer patients carrying the CRYAB C-802G CG had a significant
trend toward decreased disease-free survival, and the patients
carrying CRYAB C-802G GG had the shortest disease-free survival
period (Figure 2). The short disease-free may mainly reflect local
recurrence. More than 80% (30 of 37) of the patients carrying
CRYAB C-802G GG had nodal recurrence without an advanced N
stage (N0-1) at the first diagnosis. Interestingly, the patients would
have frequent recurrence and high second primary tumor rates
within the following five years. Second, compared with those with
CC genotype, the patients carrying CRYAB C-802G CG or GG
genotype had a higher recurrence rate within the following five
years (P=0.228, OR=2.08, 95%CI=1.11–3.92), but not a
higher metastasis rate (Table 3).
Discussion
The study aimed to investigate the association of CRYAB
genotypes and clinicopathopogical variations in Taiwan oral
cancer patients. It has recently been recognized that CRYAB
protein may play a role in oral cancer development. In previous
literature, it was reported that CRYAB was significantly over
expressed in the primary tissue from oral cancer patients in
Taiwan [10]. In 2010, in a tongue cancer mice model performed
by concomitantly 8-week treatment with 4-NQO (200 mg/mL)
and arecoline (500 mg/mL) and withdraw in the following 20
weeks, the cells of the tumor sites had higher expression of
CRYAB than the counterpart cells of the sham-treated mice [11].
However, there were also some findings challenging this up-
regulation association [9,12]. This may be due to that different
populations of different ethics, genetic background, cultures, and
environment exposure were investigated. From the viewpoints of
cell-line based studies, it was demonstrated that overexpression of
CRYAB in transformed immortalized human mammary epithelial
cells demonstrated neoplastic features and luminal growth and
these changes were inhibited when CRYAB expression was
silenced using RNA interference [13]. Overexpression of CRYAB
in human mammary epithelial cells also formed invasive
mammary carcinomas in nude mice, induced epidermal growth
factor and anchorage independent growth, increased cell migra-
tion and invasion, and activated the mitogen-activated protein
kinase/extracellular signal-regulated kinase (MEK/ERK) path-
way, suggesting that CRYAB could be considered an oncoprotein
[14]. However, there is not yet any study performed from the
DNA level to investigate the important role of CRYAB in
carcinogenesis.
Based on the previous differential expression evidence, we were
strongly interested and chose the three SNPs of CRYAB, two at the
promoter region (A-1215G and C-802G) and one at the intron 2
(intron2), to investigate their associations with oral cancer risk and
prognosis. We found that CRYAB C-802G polymorphism, not A-
1215G or intron2, was associated with increased risk of oral cancer
(Table 2), and the local recurrence rate (Table 3). Also, the oral
cancer patients carrying GG or CG at the polymorphic site had
lower 5-year survival rate than those carrying homologous CC
(Figure 2). Interestingly, the patients carrying GG at CRYAB C-
802G were recorded to have much more frequent recurrence and
second primary rates. This may indicate that CRYAB C-802G
could be a predicator for oral cancer progression direction.
Possibly the genetic polymorphism directly affects the differential
patterns of the CRYAB protein, at the expression and/or
functional levels, and indirectly imbalances the normal functions
of other CRYAB-related genes and proteins, which may result in
the oral carcinogenesis. At the same time, the alteration of
CRYAB protein expression in the extracellular matrix may cause
the subtle changes of the microenvironment near the primary oral
tumor, for the recurrence, but not for the metastasis. This can be
justified by the role of CRYAB in the tyrosine kinase signaling,
that could be easily altered in cancer cells. The reduced expression
of CRYAB has been firstly reported to be associated with a
negative prognosis in 2003 [15].
Approximately 10% of early-stage head and neck squamous cell
carcinoma patients develop locoregional recurrence and 15% to
Table 1. Characteristics of oral cancer patients and controls.
Characteristics Controls (n=992) Patients (n=496) P
a
n%
Mean
(SD) n %
Mean
(SD)
Age (y) 66.1 (9.7) 63.8 (8.4) 0.73
Gender
Male 914 92.1% 469 94.6%
Female 78 7.9% 27 5.4% 0.16
Indulgence
Cigarette smokers 526 53.0% 356 71.8% ,0.0001
Areca chewers 506 51.0% 332 66.9% ,0.0001
Alcohol drinkers 445 44.9% 299 60.3% ,0.0001
Histology
Tongue 247 49.8%
Buccal mucosa 141 28.4%
Mouth floor 29 5.8%
Retromolar trigone 20 4.0%
Alveolar ridge 13 2.6%
Palate 12 2.4%
Lip 11 2.2%
Others 23 4.6%
aP based on Chi-square test.
doi:10.1371/journal.pone.0016374.t001
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diagnosis [16,17]. As diagnostic and therapeutic approaches
continue to develop, the ability to accurately predict second
primary tumor/recurrence in early-stage oral cancer patients
would facilitate intensive surveillance or targeted interventions for
high-risk patients and thereby reduce mortality and morbidity. In
this study, the patients carrying CRYAB C-802G CG or GG
genotype were found to have a higher recurrence rate within the
following five years, but not a higher metastasis rate (Table 3).
The occurrence of second primary tumors may be due to the
subtle alterations of the microenvironment which have been
accumulated to reach the threshold of tumorigenesis in the
Table 2. Distribution of CRYAB genotypes and allelic frequencies among oral cancer patients and controls.
Polymorphism Controls % Patients % P
a OR (95% CI)
b
A-1215G (rs2228387)
Genotype
GG 981 98.9% 491 99.0% 1.00 (reference)
AG 11 1.1% 5 1.0% 0.91 (0.31–2.63)
AA 0 0% 0 0% 0.9999
Allele
G 1973 99.4% 987 99.5%
A 11 0.6% 5 0.5% 0.8593 0.91 (0.31–2.62)
C-802G (rs14133)
Genotype
CC 703 70.9% 301 60.7% 1.00 (reference)
CG 245 24.7% 158 31.9% 1.51 (1.18–1.92)
GG 44 4.4% 37 7.4% 0.0002 1.96 (1.24–3.10)
Allele
C 1651 83.2% 760 76.6% 1.00 (reference)
G 333 16.8% 232 23.4% 1.49*10
25 1.51 (1.25–1.83)
Intron2 (rs2070894)
Genotype
CC 688 69.4% 325 65.5% 1.00 (reference)
CT 268 27.0% 150 30.3% 1.18 (0.93–1.51)
TT 36 3.6% 21 4.2% 0.3241 1.23 (0.71–2.15)
Allele
C 1644 82.9% 800 80.6% 1.00 (reference)
T 340 17.1% 192 19.4% 0.1366 1.16 (0.95–1.41)
aP based on two-sided Chi-square test without Yate’s correction.
bOR: odds ratio, CI: confidence interval.
doi:10.1371/journal.pone.0016374.t002
Figure 1. PCR-based restriction analysis of the CRYAB C-802G rs14133 polymorphism shown on 2.5% agarose electrophoresis. M:
100 bp DNA size marker, G/G: enzyme indigestible homozygote, C/G: heterozygote, and C/C: enzyme digestible homozygote.
doi:10.1371/journal.pone.0016374.g001
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functional study of this SNP and how the CRYAB protein
interacts with proteins in extracellular matrix in oral carcinogen-
esis also need further investigations. In the future, collective
evidence from larger and different cohorts using this SNP may
help to oral cancer staging, outcome direction prediction, and
more effective and integrative strategy.
It is firstly found that the SNP at the promoter region of CRYAB,
C-802G, is associated with oral cancer susceptibility, recurrence,
and 5-year disease-free survival, but not metastasis. Since poor
local-regional control and easy recurrence are the main causes of
treatment failures in oral cancer therapy, the results of this study
may provide more predictive guidance information for not only
the prevention, but the care, therapy and follow-up of those
patients at higher risk of cancer recurrence and lower 5-year
survival rate.
Materials and Methods
Study population and sample collection
Four hundred and ninety six cancer patients diagnosed with
oral cancer were recruited at the outpatient clinics of general
surgery between 2005–2008 at the China Medical University
Hospital, Taichung, Taiwan, Republic of China. The clinical
characteristics of patients include histological details were all
graded and defined by expert surgeons. All patients voluntarily
participated, completed a self-administered questionnaire and
provided peripheral blood samples. Double number of non-cancer
healthy volunteers as controls were selected by matching for age,
gender and some indulgences after initial random sampling from
the Health Examination Cohort of the hospital. The exclusion
criteria of control group included previous malignancy, metasta-
sized cancer from other or unknown origin, and any familial or
Table 3. Association of CRYAB C-802G genotype with oral cancer recurrence and metastasis.
Patient Status CRYAB C-802G rs14133
CC CG+GG P
a OR (95% CI)
b
Recurrence Status
No recurrence .5 years 282 171 1.00
Recurrence ,5 years 19 24 0.0228
c 2.08 (1.11–3.92)
Metastasis Status
No metastasis .5 years 279 178 1.00
Metastasis ,5 years 22 17 0.6101 1.21 (0.63–2.34)
aP based on two-sided Chi-square test without Yate’s correction.
bThe ORs were estimated with multivariate logistic regression analysis.
cStatistically identified as significant.
doi:10.1371/journal.pone.0016374.t003
Figure 2. Disease-free survival of oral cancer patients after diagnosis stratified by genotypes of CRYAB C-802G. Statistical analysis was
performed by the log-rank test.
doi:10.1371/journal.pone.0016374.g002
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included some indulgences and they were recorded. Our study was
approved by the Institutional Review Board of the China Medical
University Hospital and written-informed consent was obtained
from all participants.
Genotyping assays
Genomic DNA from oral cancer and health control subjects were
prepared from peripheral blood leucocytes using a QIAamp Blood
Mini Kit (Blossom, Taipei, Taiwan) and further processed according
to previous studies [18–24]. Briefly, the following primers were used
for CRYAB A-1215G (rs2228387): 59-ACCTGTTGGAGTCT-
GATCTT-39 and 59-ATGCACCTCAATCACATCTC-39;f o r
CRYAB C-802G (rs14133): 59-TTGACCATCACTGCTCTCTT-
39 and 59-TTGGCAATGTGACACATACC-39;f o rCRYAB intron
2 (rs2070894): 59-GTCTAGAAGACTAAGTTAGG-39 and 59-
AGAGAAGTCACAACTCAAGT-39; The following cycling condi-
tions were performed: one cycle at 94uCf o r5m i n ;3 5c y c l e so f9 4 uC
for 30 s, 55uCf o r3 0s ,a n d7 2 uC for 30 s; and a final extension at
72uC for 10 min. The PCR products were studied after digestion
with Fau I, Fat I,a n dDPN I, restriction enzymes for A-1215G (cut
from 212 bp A type into 67+145 bp G type), C-802G (cut from 363
bp G type into 85+278 bp C type), and intron 2 (cut from 363 bp T
type into 74+339 bp C type), respectively.
Statistical analyses
In our study, only those matches with all SNPs data (case/
control =496/992) were selected into final analyzing. To ensure
that the controls used were representative of the general
population and to exclude the possibility of genotyping error,
the deviation of the genotype frequencies of CRYAB SNPs in the
control subjects from those expected under the Hardy-Weinberg
equilibrium was assessed using the goodness-of-fit test. Pearson’s
two-sided Chi-square test or Fisher’s exact test (when the expected
number in any cell was less than five) was used to compare the
distribution of the CRYAB genotypes between cases and controls.
The primary outcome was disease-free survival. The endpoints
included local cancer recurrence and metastasis. Follow-up
information was available for all patients at the 5-year time point.
Disease-free survival time was calculated from the date of
treatment until the time of recurrence, defined as disease
recurrence at the same site or the detection of metastases,
including recurrence in the neck lymph nodes. The genotypes
were coded assuming an allele dose-effect (CC wild-type=0, CG
heterozygous carrier of the mutated allele=1, GG homozygous
carrier of the mutated allele=2). Disease-free survival curves were
generated by the Kaplan-Meier method and verified by the log-
rank test. The significance level was set at P,0.05.
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